A Dosing/Cross-Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) and cancer share elements of pathophysiology. This provides an opportunity for the cross-development of anticancer agents that can be used in improving PAH care. The adaptation of new drugs across these disease populations warrants a structured approach. This st...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Gomberg-Maitland, M, Maitland, ML, Barst, RJ, Sugeng, L, Coslet, S, Perrino, TJ, Bond, L, LaCouture, ME, Archer, SL, Ratain, MJ
Format: Artigo
Langue:Inglês
Publié: 2009
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3291104/
https://ncbi.nlm.nih.gov/pubmed/20010555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/clpt.2009.217
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires